2. Search Result
Search Result
Isoforms Recommended: PLD
Results for "

PLD2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150412
    VU0364739

    		Phospholipase Cancer
    VU0364739 is a selective PLD2 inhibitor (IC50: 22 nM). VU0364739 decreases cancer cell proliferation .
    VU0364739
  • HY-116165
    ML-298

    		Phospholipase Cancer
    ML298 is a potent and selective inhibitor of Phospholipase D2 (PLD2) with an IC50 of 355 nM. ML298 decreases invasive migration in U87-MG glioblastoma cells .
    ML-298
  • HY-RS10671
    PLD2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PLD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PLD2 Human Pre-designed siRNA Set A
    PLD2 Human Pre-designed siRNA Set A
  • HY-108612A
    VU0155069 hydrochloride

    CAY10593 hydrochloride

    		 Phospholipase Cancer
    VU0155069 hydrochloride (CAY10593 hydrochloride) is a potent selective phospholipase D (PLD) inhibitor. The IC50 values for PLD1 and PLD2 are 46 and 933 nM, respectively. VU0155069 hydrochloride inhibits migration of human and mouse breast cancer cell lines [2].
    VU0155069 hydrochloride
  • HY-108616
    VU 0364739 hydrochloride

    		Phospholipase Cancer
    VU 0364739 hydrochloride is a highly selective phospholipase D2 (PLD2) inhibitor with IC50s of 20 and 1500 nM for PLD2 and PLD1, respectively. VU 0364739 hydrochloride induces apoptosis and it can be used for cancer research .
    VU 0364739 hydrochloride
  • HY-12807
    FIPI
    4 Publications Verification

    5-Fluoro-2-indolyl deschlorohalopemide

    		 Phospholipase Autophagy Inflammation/Immunology Cancer
    FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research [2] .
    FIPI
  • HY-12807A
    FIPI hydrochloride

    5-Fluoro-2-indolyl deschlorohalopemide hydrochloride

    		 Phospholipase Autophagy Inflammation/Immunology Cancer
    FIPI (5-Fluoro-2-indolyl des-chlorohalopemide) hydrochloride, a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI hydrochloride inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI hydrochloride has the potential for autoimmunity and cancer metastasis research [2] .
    FIPI hydrochloride
  • HY-155343
    A4333

    		Phospholipase Cancer
    A4333 is biotinylated compound of A3373 (HY-155342) that inhibits Phospholipase D1 (PLD1), but not PLD2. A4333 plays an important role in antitumor activity .
    A4333
  • HY-119093
    Halopemide

    		Phospholipase Dopamine Receptor Neurological Disease Cancer
    Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent [2].
    Halopemide
  • HY-155342
    A3373

    		Phospholipase Inflammation/Immunology
    A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis [2].
    A3373
  • HY-142980
    Dioleoylphosphatidylglycerol

    DOPG

    		 Liposome Inflammation/Immunology
    Dioleoylphosphatidylglycerol (DOPG) is a naturally occurring phospholipid that can be produced by the combined action of aquaporin 3 (AQP3) and phospholipase D2 (PLD2). Dioleoylphosphatidylglycerol inhibits macrophage inflammatory mediator production in response to heat shock protein B4 (HSPB4) activation of toll-like receptor 2 (TLR2) .
    Dioleoylphosphatidylglycerol
  • HY-114095
    BML-280

    VU0285655-1

    		 Phospholipase TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology Cancer
    BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research [2].
    BML-280
  • HY-121983
    CAY10594

    		Phospholipase Cancer
    CAY10594 is a potent phospholipase D2 (PLD2) inhibitor both in vitro (IC50=140 nM) and in cells (IC50=110 nM) . CAY10594 strongly inhibits the invasive migration of breast cancer cells in vitro and ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis [2].
    CAY10594
  • HY-101293
    VU0359595

    CID-53361951; ML-270

    		 Phospholipase Fungal Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases [2] .
    VU0359595

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: